Peripheral T-Cell Lymphoma: What's Next?

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous cancer with over 30 subtypes.
• Current treatments often use CHOP regimens, originally designed for B-cell lymphomas, with limited success in PTCL.
• The complexity of PTCL reflects its diverse genetic and biological underpinnings.

Purpose of the Study:

• To review the classification and treatment landscape of PTCL.
• To highlight the limitations of current empirical treatment strategies.
• To advocate for biologically-guided future therapeutic approaches for PTCL.

Main Methods:

• Literature review of PTCL classification and treatment studies.
• Analysis of clinical trial outcomes, including the ECHELON-2 trial.
• Discussion of the biological diversity influencing treatment response.

Main Results:

• The International Consensus Classification (ICC) and WHO-HEM 2022 recognize over 30 PTCL subtypes.
• Standard CHOP-based regimens have shown limited efficacy across PTCL subtypes.
• The ECHELON-2 trial demonstrated success with brentuximab vedotin (BV) in anaplastic large cell lymphoma (ALCL), a specific PTCL subtype.

Conclusions:

• Future PTCL treatment strategies must be informed by a deeper understanding of disease biology.
• Reliance on empirical approaches extrapolated from other lymphomas is insufficient.
• Personalized, biologically-driven therapies are essential for improving outcomes in PTCL.